000097452 001__ 97452
000097452 005__ 20210902121934.0
000097452 0247_ $$2doi$$a10.3389/fphar.2020.586187
000097452 0248_ $$2sideral$$a121699
000097452 037__ $$aART-2020-121699
000097452 041__ $$aeng
000097452 100__ $$aGuerrero-Fernández de Alba, I.
000097452 245__ $$aComorbidity in an Older Population with Type-2 Diabetes Mellitus: Identification of the Characteristics and Healthcare Utilization of High-Cost Patients
000097452 260__ $$c2020
000097452 5060_ $$aAccess copy available to the general public$$fUnrestricted
000097452 5203_ $$aObjectives: Little is known about the specific comorbidities contributing to higher costs in patients with type-2 diabetes mellitus (T2DM), particularly in older cases. We aimed to evaluate the prevalence, type, and cost of comorbidities occurring in older T2DM patients versus older non-T2DM patients, and the factors associated with high cost (HC) T2DM patients.
Methods: Retrospective cohort study using information from the Campania Region healthcare database. People aged =65 years who received =2 prescriptions for antidiabetic drugs were identified as “T2DM patients.” Comorbidities among T2DM and non-T2DM groups were assessed through the RxRiskV Index (modified version). T2DM individuals were classified according to the total cost distribution as HC or “non-high cost.” Two sub-cohorts of HC T2DM patients were assessed: above 90th and 80th percentile of the total cost. Age- and sex-adjusted logistic regression models were created.
Results: Among the T2DM cohort, concordant and discordant comorbidities occurred significantly more frequently than in the non-T2DM cohort. Total mean annual cost per T2DM patient due to comorbidities was €7, 627 versus €4, 401 per non-T2DM patient. Among T2DM patients identified as being above 90th and 80th percentiles of cost distribution, the total annual costs were >€19, 577 and >€2, 563, respectively. The hospitalization cost was higher for T2DM cases. Strongest predictors of being a HC T2DM patient were having =5 comorbidities and renal impairment.
Conclusion: HC patients accrued >80% of the total comorbidities cost in older T2DM patients. Integrated care models, with holistic and patient-tailored foci, could achieve more effective T2DM care.
000097452 540__ $$9info:eu-repo/semantics/openAccess$$aby$$uhttp://creativecommons.org/licenses/by/3.0/es/
000097452 590__ $$a5.81$$b2020
000097452 591__ $$aPHARMACOLOGY & PHARMACY$$b40 / 275 = 0.145$$c2020$$dQ1$$eT1
000097452 592__ $$a1.383$$b2020
000097452 593__ $$aPharmacology (medical)$$c2020$$dQ1
000097452 593__ $$aPharmacology$$c2020$$dQ1
000097452 655_4 $$ainfo:eu-repo/semantics/article$$vinfo:eu-repo/semantics/publishedVersion
000097452 700__ $$aOrlando, V.
000097452 700__ $$aMonetti, V.M.
000097452 700__ $$aMucherino, S.
000097452 700__ $$0(orcid)0000-0002-5440-1710$$aGimeno-Miguel, A.
000097452 700__ $$aVaccaro, O.
000097452 700__ $$aForjaz, M.J.
000097452 700__ $$0(orcid)0000-0002-5119-5093$$aPoblador Plou, B.
000097452 700__ $$aPrados-Torres, A.
000097452 700__ $$aRiccardi, G.
000097452 700__ $$aMenditto, E.
000097452 773__ $$g11 (2020), 586187 [11 pp]$$pFront. pharmacol.$$tFrontiers in pharmacology$$x1663-9812
000097452 8564_ $$s633588$$uhttps://zaguan.unizar.es/record/97452/files/texto_completo.pdf$$yVersión publicada
000097452 8564_ $$s25269$$uhttps://zaguan.unizar.es/record/97452/files/texto_completo.jpg?subformat=icon$$xicon$$yVersión publicada
000097452 909CO $$ooai:zaguan.unizar.es:97452$$particulos$$pdriver
000097452 951__ $$a2021-09-02-10:57:04
000097452 980__ $$aARTICLE